The IBD SmartSelect Composite Rating for LeMaitre Vascular rose from 94 to 96 Friday.
The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
LeMaitre Vascular is now out of buy range after breaking out from a 92.90 entry in a flat base.
Discover The 3 Keys To Successful Stock Investing
The stock earns a 94 EPS Rating, meaning its recent quarterly and annual earnings growth tops 94% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q3, the company reported 48% earnings-per-share growth. Revenue growth rose 16%, up from 11% in the prior report. That marks one quarter of accelerating revenue gains.
LeMaitre Vascular holds the No. 1 rank among its peers in the Medical-Products industry group. Insulet and Bioventus are also among the group's highest-rated stocks.
